Treatment of newly diagnosed patients with myasthenia gravis at a regional hospital in years 2003–2013
Abstract
Background: Myasthenia gravis (MG) is the most common autoimmune disorders of the neuromuscular junction. Advances in intensive care in conjunction with the advent of novel treatments have made MG one of the most treatable neurological disorders. The incidence and prevalence rates of MG have increased over time due to greater disease awareness, better diagnostic methods and ageing of the population. Due to these facts, the number of MG patients evaluated at the secondarylevel regional hospitals has increased. So far, no data on the evaluation of MG in Slovenia have been systematically collected. The aim and scope of this article is to present the analysis of the evaluation of newly diagnosed MG patients at the General hospital of Isola for the time period between 1 January 2003 and 31 December 2013.
Methods: We reviewed medical files of MG patients diagnosed at the General hospital of Isola in the above mentioned time period and collected data on patients’ demographic and clinical characteristics in addition to examining their clinical course and treatment outcome.
Results: Twenty-nine patients were identified (14 women, 15 men). Te mean age at disease onset was 59.4 ± 21.2 years for women and 56.3 ± 19.8 years for men. In the study population, 58.6 % of the patients were acetylcholine receptor antibody positive. Besides MG, patients most often had thyroid and other chronic diseases. Most patients (68.9 %) presented with extraocular disease symptoms, which progressed to generalized disease in 65 % of cases. Myasthenic crisis occurred in 10.3 % of patients. In 68.9 % of cases, the patients were treated exclusively with symptomatic therapy. Tymectomy was performed in 13.7 % of cases. On treatment, 13.7 % achieved a stable complete remission of MG symptoms, in 55 % the condition substantially improved, in 20.6 % improvement was only partial, and in 6.8 % of patients the condition remained unchanged. The fiveyear mortality of the study population, estimated according to the Kaplan-Meier method was 13.5 %.
Conclusions: With the exception of a higher mortality rate, the patients’ characteristics and clinical course of the disease were similar to data reported in other epidemiological studies. The patients’ higher mortality rate was considered to be a consequence of the lack of intensive treatment in patients with myasthenic crisis due to the unawareness of the reversibility of the condition with an adequate treatment.
Downloads
References
Verschuuren JJGM, Palace J, Erik Gilhus N. Clinical aspects of myasthenia explained. Autoimmunity. 2010;43(5–6):344–52.
Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle & Nerve. 2008;37(2):141–9.
Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA. Myasthenia Gravis: A Review of Available Treatment Approaches. Autoimmune Diseases. 2011;2011:1–6.
Daroff RB, Fenichel GM, Jankovic J, Mazziotta JC. Preface. Neurology in Clinical Practice: Elsevier BV; 2012. p. xiv-xv.
Jacob S, Viegas S, Lashley D, Hilton-Jones D. Myasthenia gravis and other neuromuscular junction disorders. Practical Neurology. 2009;9(6):364–71.
Sathasivam S. Diagnosis and management of myasthenia gravis. Progress in Neurology and Psychiatry. 2014;18(1):6–14.
Rowin J. Approach to the patient with suspected myasthenia gravis or ALS. Continuum: Lifelong Learning in Neurology. 2009;15:13–34.
Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. The Lancet Neurology. 2009;8(5):475–90.
Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis — autoantibody characteristics and their implications for therapy. Nature Reviews Neurology. 2016;12(5):259–68.
Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classifcation and therapeutic strategies. The Lancet Neurology. 2015;14(10):1023–36.
Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia Gravis: A Review. Autoimmune Diseases. 2012;2012:1–10.
Hoffmann S, Kohler S, Ziegler A, Meisel A. Glucocorticoids in myasthenia gravis–if, when, how, and how much? Acta Neurologica Scandinavica. 2014;130(4):211–21.
Pakzad Z, Aziz T, Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology. 2011;76(17):1526–8.
Heldal AT, Owe JF, Gilhus NE, Romi F. Seropositive myasthenia gravis: A Nationwide epidemiologic study. Neurology. 2009;73(2):150–1.
Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. European Journal of Neurology. 2010;17(12):1445–50.
Pallaver F, Riviera AP, Piffer S, Ricciardi R, Roni R, Orrico D, et al. Change in Myasthenia Gravis Epidemiology in Trento, Italy, afer Twenty Years. Neuroepidemiology. 2011;36(4):282–7.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
